Overview

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Status:
Not yet recruiting
Trial end date:
2024-07-20
Target enrollment:
Participant gender:
Summary
The study consists of the two parts, phase IIa and phase IIb.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Kechow Pharma, Inc.
Treatments:
Vemurafenib